Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 10/20 | 0.50 |
| ▸ | PGK2 | P07205 | 10/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | PTPRB | P23467 | 2/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241084 | 0.84 | PGK1 (0.35) | PGK1PGK2ENPP2 | |
| SCHEMBL240726 | 0.82 | PGK1 (0.54) | PGK1PGK2ENPP2PTPRBACP3 | |
| SCHEMBL240691 | 0.82 | PGK1 (0.44) | PGK1PGK2ENPP2PTPRBACP3 | |
| SCHEMBL1617420 | 0.82 | PGK1 (0.67) | PGK1PGK2ENPP2PTPRBACP3 | |
| SCHEMBL241256 | 0.77 | GRIN2D (0.43) | ACP3 | |
| SCHEMBL10967058 | 0.77 | LAP3 (0.34) | PGK1PGK2ENPP2SMN1; SMN2 | |
| SCHEMBL6770911 | 0.76 | PPARD (0.42) | ENPP2 | |
| SCHEMBL9407120 | 0.75 | PGK1 (0.59) | PGK1PGK2ENPP2PTPRBACP3 | |
| Benzylphosphonic Acid SCHEMBL44318 | 0.75 | HPGD (0.60) | PGK1PGK2ACP3 | |
| SCHEMBL6518091 | 0.74 | PGK1 (0.43) | PGK1PGK2ACP3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8231941-B2 | Procedure for preparing redox-active polymers on surfaces | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-31 | — | — | US | claimed |
| US-20100330284-A1 | PROCEDURE FOR PREPARING REDOX-ACTIVE POLYMERS ON SURFACES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-30 | — | — | US | claimed |
| CN-100577410-C | Method for preparing redox-active polymers on surfaces | UNIV CALIFORNIA | 2010-01-06 | — | — | CN | claimed |
| US-7452572-B1 | Procedure for preparing redox-active polymers on surfaces | THE NORTH CAROLINA STATE UNIVERSITY (US) | 2008-11-18 | — | — | US | claimed |
| US-20080280047-A1 | PROCEDURE FOR PREPARING REDOX-ACTIVE POLYMERS ON SURFACES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-11-13 | — | — | US | claimed |
| US-7312100-B2 | In situ patterning of electrolyte for molecular information storage devices | THE NORTH CAROLINA STATE UNIVERSITY (US) | 2007-12-25 | — | — | US | claimed |
| EP-1809473-A2 | PROCEDURE FOR PREPARING REDOX-ACTIVE POLYMERS ON SURFACES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-07-25 | — | — | EP | claimed |
| CN-1984775-A | Method for preparing redox-active polymers on surfaces | UNIV CALIFORNIA (US) | 2007-06-20 | — | — | CN | claimed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | claimed |
| US-7037912-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2006-05-02 | — | — | US | claimed |
| WO-2005086826-A2 | PROCEDURE FOR PREPARING REDOX-ACTIVE POLYMERS ON SURFACES | THE REGENTS OF THE UNIVERSITY (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050207208-A1 | Situ patterning of electrolyte for molecular information storage devices | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-09-22 | — | — | US | claimed |
| US-6944047-B2 | Variable-persistence molecular memory devices and methods of operation thereof | NORTH CAROLINA STATE UNIVERSITY (US) | 2005-09-13 | — | — | US | claimed |
| WO-2005017953-A2 | IN SITU PATTERNING OF ELECTROLYTE FOR MOLECULAR INFORMATION STORAGE DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-24 | — | — | WO | claimed |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-11-25 | — | — | US | claimed |
| US-20040120180-A1 | Variable-persistence molecular memory devices and methods of operation thereof | NORTH CAROLINA STATE UNIVERSITY | 2004-06-24 | — | — | US | claimed |
| US-6750241-B2 | Protein kinase inhibitors | THERAVANCE, INC. | 2004-06-15 | — | — | US | claimed |
| US-20020177600-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-11-28 | — | — | US | claimed |
| US-20020002169-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-01-03 | — | — | US | claimed |
| WO-2001042243-A2 | PROTEIN KINASE INHIBITORS | ADVANCED MEDICINE, INC. (US) | 2001-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177600-A1 | Protein kinase inhibitors | MAP3K20, MAP3K9, MAP3K6 | PGK1 300/4885PGK2 264/4885ENPP2 1382/4885 |
| US-20020002169-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | PGK1 297/4885PGK2 244/4885ENPP2 1343/4885 |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | UACA, PRKDC, CDK2 | PGK1 368/4885PGK2 299/4885ENPP2 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.